TY  - JOUR
AU  - Bernabe, Reyes
AU  - Patrao, Ana
AU  - Carter, Louise
AU  - Blackhall, Fiona
AU  - Dean, Emma
PY  - 2016
DO  - 10.2217/fon-2016-0132
SN  - 1479-6694
UR  - http://hdl.handle.net/10668/19200
T2  - Future oncology
AB  - The RAS-RAF-MEK-ERK pathway regulates processes involved in the proliferation and survival of cells. KRAS mutations, prevalent in approximately 30% of patients with non-small-cell lung cancer ( NSCLC), result in constitutive activation of the pathway....
LA  - en
PB  - Future medicine ltd
KW  - MEK inhibitor
KW  - non-small-cell lung cancer
KW  - selumetinib
KW  - Phase-ii trial
KW  - Oral mek inhibitor
KW  - Kras-mutant
KW  - Open-label
KW  - Azd6244 arry-142886
KW  - Clinical-trial
KW  - Plus docetaxel
KW  - Multicenter
KW  - Efficacy
KW  - Chemotherapy
TI  - Selumetinib in the treatment of non-small-cell lung cancer
TY  - research article
VL  - 12
ER  -